OrganoTherapeutics uses cutting-edge human-specific midbrain organoids for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary organoids which mimic faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.
Company Details
- Employees
- 9
- Address
- 6a, Avenue Des Hauts-Fourneaux, Esch-Sur-Alzette,luxemburg L-4365,luxembourg
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://organo-therapeutics.com/
- Keywords
- Software Development.
- HQ
- Esch-sur-Alzette, Luxemburg
Organotherapeutics Questions
Organotherapeutics's website is http://organo-therapeutics.com/
Organotherapeutics's LinkedIn profile is https://lu.linkedin.com/company/organotherapeutics
Organotherapeutics has
9 employees.
View email and phone details for 9
employees at Organotherapeutics.
Organotherapeutics's industry is
Biotechnology Research
Organotherapeutics's top competitors are
Silcube Financial Systems,
Nium,
Essembl,
Moveme,
House Of Biohealth,
Mitotech,
Luxembourg Bio Technologies Ltd.,
Augment - Digital Facilities Services,
Exobiosphere,
Luxbiotech Corporate.
Organotherapeutics's categories are Biotechnology Research
